Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma

A. J. Davies, A. Z.S. Rohatiner, S. Howell, K. E. Britton, S. E. Owens, I. N. Micallef, D. P. Deakin, B. M. Carrington, J. A. Lawrance, S. Vinnicontbe, S. J. Mather, J. Clayton, R. Foley, H. Jan, S. Kroll, M. Harris, J. Amess, A. J. Norton, T. A. Lister, J. A. Radford

Research output: Contribution to journalArticle

95 Scopus citations

Abstract

Purpose: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. Patients and Methods: A single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 × 109/L). Forty of 41 patients received both infusions. Results: Thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(U)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient. Conclusion: High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed.

Original languageEnglish (US)
Pages (from-to)1469-1479
Number of pages11
JournalJournal of Clinical Oncology
Volume22
Issue number8
DOIs
StatePublished - Dec 1 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Davies, A. J., Rohatiner, A. Z. S., Howell, S., Britton, K. E., Owens, S. E., Micallef, I. N., Deakin, D. P., Carrington, B. M., Lawrance, J. A., Vinnicontbe, S., Mather, S. J., Clayton, J., Foley, R., Jan, H., Kroll, S., Harris, M., Amess, J., Norton, A. J., Lister, T. A., & Radford, J. A. (2004). Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 22(8), 1469-1479. https://doi.org/10.1200/JCO.2004.06.055